Calidi Biotherapeutics to Unveil CLD-401 Data at AACR 2026, Eyes IND Filing by Year-End
Event summary
- Calidi Biotherapeutics will present new data on CLD-401 at the AACR annual meeting from April 17-22, 2026.
- CLD-401 is a systemically delivered oncolytic virus designed to express high levels of IL-15 superagonist in the tumor microenvironment.
- The company expects to file an IND for CLD-401 by the end of 2026.
- CLD-401 targets non-small cell lung cancer, head and neck cancer, and other tumor types with high unmet medical need.
The big picture
Calidi Biotherapeutics is positioning itself as a leader in targeted genetic medicines with its RedTail platform. The upcoming AACR presentation and planned IND filing for CLD-401 are critical milestones that could validate the platform's ability to selectively target tumors and remodel the tumor microenvironment. The company's focus on high-unmet-need indications like non-small cell lung cancer and head and neck cancer aligns with broader industry trends toward precision oncology.
What we're watching
- Clinical Timelines
- Whether Calidi can meet its goal of filing an IND for CLD-401 by the end of 2026.
- Data Impact
- How the AACR data presentation will influence investor and partner perceptions of CLD-401's potential.
- Platform Expansion
- The pace at which Calidi can advance its RedTail platform beyond CLD-401.
Related topics